Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| INSM - Insmed | 13.11% | Reduce −43.2% | 491,805 | $144.01 | $71M | −373,308 | −$16M |
| PTC - Ptc Therapeutics | 9.80% | Add +112.2% | 862,613 | $61.37 | $53M | +456,144 | +$33M |
| ACAD - Acadia Pharmaceuticals | 9.74% | Reduce −3.8% | 2,466,684 | $21.34 | $53M | −96,525 | −$3M |
| FOLD - Amicus | 7.83% | Reduce −4.3% | 5,367,798 | $7.88 | $42M | −242,715 | +$10M |
| BMRN - Biomarin Pharmaceutical | 7.56% | Reduce −10.3% | 754,007 | $54.16 | $41M | −86,463 | −$5M |
| BIIB - Biogen | 4.81% | Reduce −9.8% | 185,661 | $140.08 | $26M | −20,098 | +$166K |
| UTHR - United Therapeutics | 4.51% | Reduce −39.1% | 58,186 | $419.21 | $24M | −37,296 | −$3M |
| ANAB - Anaptysbio | 3.82% | Reduce −17.1% | 673,520 | $30.62 | $21M | −139,301 | +$3M |
| IOVA - Iovance Biotherapeutics | 3.06% | Add +122.1% | 7,618,132 | $2.17 | $17M | +4,188,803 | +$11M |
| NVCR - Novocure | 3.00% | Add +30.5% | 1,256,159 | $12.92 | $16M | +293,763 | −$901K |
| DYN - Dyne Therapeutics | 2.96% | Add +376.5% | 1,262,674 | $12.65 | $16M | +997,698 | +$13M |
| IRON - Disc Medicine | 2.74% | Add +54.0% | 224,300 | $66.08 | $15M | +78,609 | +$7M |
| ALNY - Alnylam Pharmaceuticals | 2.73% | Reduce −57.2% | 32,320 | $456.00 | $15M | −43,215 | −$10M |
| Gossamer Bio | 2.66% | Reduce −4.8% | 5,464,349 | $2.63 | $14M | −274,664 | +$7M |
| PRTA - Prothena · CL A | 2.39% | Add +3.9% | 1,324,028 | $9.76 | $13M | +49,275 | +$5M |
| RARE — | 2.06% | Add +658.0% | 369,531 | $30.08 | $11M | +320,781 | +$9M |
| AGIO - Agios Pharmaceuticals | 1.97% | Reduce −1.2% | 265,497 | $40.14 | $11M | −3,286 | +$2M |
| SNDX - Syndax Pharmaceuticals | 1.86% | Add +47.4% | 654,930 | $15.38 | $10M | +210,563 | +$6M |
| EHTH - Ehealth | 1.23% | Reduce −2.1% | 1,544,619 | $4.31 | $7M | −33,231 | −$206K |
| DNLI - Denali Therapeutics | 1.10% | Add +70.1% | 408,006 | $14.52 | $6M | +168,197 | +$3M |
| ALGN - Align Technology | 1.06% | Add +21.1% | 45,735 | $125.22 | $6M | +7,963 | −$1M |
| ALKS - Alkermes | 1.02% | Reduce −16.8% | 183,938 | $30.00 | $6M | −37,083 | −$805K |
| RNAGBP - Avidity Biosciences | 0.89% | Reduce −7.6% | 109,831 | $43.57 | $5M | −9,055 | +$1M |
| MIRM - Mirum Pharmaceuticals | 0.88% | Hold | 64,700 | $73.31 | $5M | — | — |
| CDNA - Caredx | 0.85% | New | 316,204 | $14.54 | $5M | +316,204 | +$5M |
| TSHA - Taysha Gene Therapies | 0.75% | Hold | 1,246,033 | $3.27 | $4M | — | — |
| NUVB - Nuvation Bio · CL A | 0.70% | Add +32.1% | 1,020,547 | $3.70 | $4M | +247,895 | +$2M |
| ACRS - Aclaris Therapeutics | 0.55% | Add +12.7% | 1,566,840 | $1.90 | $3M | +176,812 | +$1M |
| CRSP - Crispr Therapeutics AG | 0.49% | Reduce −7.6% | 41,226 | $64.81 | $3M | −3,399 | +$501K |
| TVTX - Travere Therapeutics | 0.49% | Hold | 110,719 | $23.90 | $3M | — | — |
| EW - Edwards Lifesciences | 0.48% | Reduce −14.8% | 33,640 | $77.77 | $3M | −5,833 | −$471K |
| NBIX - Neurocrine Biosciences | 0.47% | Add +35.9% | 18,117 | $140.38 | $3M | +4,783 | +$867K |
| STOK - Stoke Therapeutics | 0.46% | Reduce −16.2% | 105,427 | $23.50 | $2M | −20,434 | +$1M |
| PYXS - Pyxis Oncology | 0.43% | Hold | 1,037,421 | $2.22 | $2M | — | — |
| BNTX - Biontech Se- | 0.36% | Reduce −22.2% | 19,614 | $98.62 | $2M | −5,592 | −$749K |
| BCYC — | 0.32% | Reduce −11.2% | 221,071 | $7.74 | $2M | −27,863 | −$19K |
| ALDX - Aldeyra Therapeutics | 0.22% | Hold | 225,465 | $5.22 | $1M | — | — |
| HUM - Humana | 0.19% | Hold | 3,985 | $260.17 | $1M | — | — |
| ORKA - Oruka Therapeutics | 0.15% | New | 59,985 | $13.19 | $791K | +59,985 | +$791K |
| ABEO - Abeona Therapeutics | 0.11% | Hold | 108,865 | $5.28 | $575K | — | — |
| URGN - Urogen Pharma | 0.09% | Hold | 24,500 | $19.95 | $489K | — | — |
| PRQR - Proqr Therapeutics | 0.07% | New | 188,807 | $2.13 | $402K | +188,807 | +$402K |
| Akari Therapeutics - | 0.03% | Hold | 146,024 | $1.01 | $147K | — | — |
| Generation Bio | 0.02% | Reduce −90.0% | 15,047 | $6.12 | $92K | −135,428 | +$44K |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q2
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Staar Surgical | 2.83% | Exit | 0 | $16.78 | $13M | −791,879 | −$13M |
| KPTI - Karyopharm Therapeutics | 0.17% | Exit | 0 | $4.31 | $810K | −187,911 | −$810K |
| Vyne Therapeutics Pipe | 0.16% | Exit | 0 | $1.65 | $735K | −445,434 | −$735K |
| ALMS - Alumis | 0.09% | Exit | 0 | $3.00 | $430K | −143,437 | −$430K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2